Intelligence Feed event · Equity · 2026-09-09

    Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms Full-Year 2026 Guidance

    Question

    Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms Full-Year 2026 Guidance

    Direct answer

    Dentsply Sirona reported second-quarter financial results marked by adjusted earnings per share of $0.52, surpassing the analyst consensus estimate of $0.36. Consolidated revenues declined 4.1% year-over-year, cushioned by a 7.1% growth contribution from the Wellspect Healthcare segment. Management maintained its full-year 2026 outlook, calling for net sales between $3.5 billion and $3.6 billion alongside adjusted earnings of $1.40 to $1.50 per share.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms Full-Year 2026 Guidance”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/dentsply-sirona-beats-q2-eps-at-0-52-and-affirms-full-year-2026-guidance-47b6cb

    EQUITY
    Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms Full-Year 2026 Guidance
    Dentsply Sirona reported second-quarter financial results marked by adjusted earnings per share of $0.52, surpassing the analyst consensus estimate of $0.36. Consolidated revenues declined 4.1% year-over-year, cushioned by a 7.1% growth contribution from the Wellspect Healthcare segment. Management maintained its full-year 2026 outlook, calling for net sales between $3.5 billion and $3.6 billion alongside adjusted earnings of $1.40 to $1.50 per share.
    XRAYALGN
    Impact
    68
    SEP 9
    SIG
    86%
    XRAYALGN
    Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms Full-Year 2026 Guidance
    Dentsply Sirona reported second-quarter financial results marked by adjusted earnings per share of $0.52, surpassing the analyst consensus estimate of $0.36. Consolidated revenues declined 4.1% year-over-year, cushioned by a 7.1% growth contribution from the Wellspect Healthcare segment. Management maintained its full-year 2026 outlook, calling for net sales between $3.5 billion and $3.6 billion alongside adjusted earnings of $1.40 to $1.50 per share.
    → Adjusted EPS outperformance of $0.52 versus $0.36 expected and 7.1% Wellspect growth offset a 4.1% revenue decline to support Dentsply Sirona's $1.40 to $1.50 full-year EPS guidance range.
    Impact
    Dentsply Sirona reported second-quarter financial results marked by adjusted earnings per share of $0.52, surpassing the analyst consensus estimate of $0.36. Consolidated revenues declined 4.1% year-over-year, cushioned by a 7.1% growth contribution from the Wellspect Healthcare segment. Management maintained its full-year 2026 outlook, calling for net sales between $3.5 billion and $3.6 billion alongside adjusted earnings of $1.40 to $1.50 per share.
    Affected
    XRAYALGN
    Transmission
    Adjusted EPS outperformance of $0.52 versus $0.36 expected and 7.1% Wellspect growth offset a 4.1% revenue decline to support Dentsply Sirona's $1.40 to $1.50 full-year EPS guidance range.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    XRAYearnings beat offset by top-line revenue contractionMixed1-5dAdjusted EPS reached $0.52 vs $0.36 consensus while revenue fell 4.1% YoY.
    ALGNdental equipment equipment demand read-acrossWatch1-4wAlign Technology operates in the dental consumables and equipment peer group.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XRAYMixed10.72 2026-09-09-2.05%-5.41%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month